First Time Loading...

Novavax Inc
NASDAQ:NVAX

Watchlist Manager
Novavax Inc Logo
Novavax Inc
NASDAQ:NVAX
Watchlist
Price: 4.15 USD -0.95% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. [ Read More ]

The intrinsic value of one NVAX stock under the Base Case scenario is 8.32 USD. Compared to the current market price of 4.15 USD, Novavax Inc is Undervalued by 50%.

Key Points:
NVAX Intrinsic Value
Base Case
8.32 USD
Undervaluation 50%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Novavax Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NVAX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Novavax Inc

Provide an overview of the primary business activities
of Novavax Inc.

What unique competitive advantages
does Novavax Inc hold over its rivals?

What risks and challenges
does Novavax Inc face in the near future?

Has there been any significant insider trading activity
in Novavax Inc recently?

Summarize the latest earnings call
of Novavax Inc.

What significant events have occurred
in Novavax Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Novavax Inc.

Provide P/S
for Novavax Inc.

Provide P/E
for Novavax Inc.

Provide P/OCF
for Novavax Inc.

Provide P/FCFE
for Novavax Inc.

Provide P/B
for Novavax Inc.

Provide EV/S
for Novavax Inc.

Provide EV/GP
for Novavax Inc.

Provide EV/EBITDA
for Novavax Inc.

Provide EV/EBIT
for Novavax Inc.

Provide EV/OCF
for Novavax Inc.

Provide EV/FCFF
for Novavax Inc.

Provide EV/IC
for Novavax Inc.

Show me price targets
for Novavax Inc made by professional analysts.

What are the Revenue projections
for Novavax Inc?

How accurate were the past Revenue estimates
for Novavax Inc?

What are the Net Income projections
for Novavax Inc?

How accurate were the past Net Income estimates
for Novavax Inc?

What are the EPS projections
for Novavax Inc?

How accurate were the past EPS estimates
for Novavax Inc?

What are the EBIT projections
for Novavax Inc?

How accurate were the past EBIT estimates
for Novavax Inc?

Compare the revenue forecasts
for Novavax Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Novavax Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Novavax Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Novavax Inc compared to its peers.

Compare the P/E ratios
of Novavax Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Novavax Inc with its peers.

Analyze the financial leverage
of Novavax Inc compared to its main competitors.

Show all profitability ratios
for Novavax Inc.

Provide ROE
for Novavax Inc.

Provide ROA
for Novavax Inc.

Provide ROIC
for Novavax Inc.

Provide ROCE
for Novavax Inc.

Provide Gross Margin
for Novavax Inc.

Provide Operating Margin
for Novavax Inc.

Provide Net Margin
for Novavax Inc.

Provide FCF Margin
for Novavax Inc.

Show all solvency ratios
for Novavax Inc.

Provide D/E Ratio
for Novavax Inc.

Provide D/A Ratio
for Novavax Inc.

Provide Interest Coverage Ratio
for Novavax Inc.

Provide Altman Z-Score Ratio
for Novavax Inc.

Provide Quick Ratio
for Novavax Inc.

Provide Current Ratio
for Novavax Inc.

Provide Cash Ratio
for Novavax Inc.

What is the historical Revenue growth
over the last 5 years for Novavax Inc?

What is the historical Net Income growth
over the last 5 years for Novavax Inc?

What is the current Free Cash Flow
of Novavax Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Novavax Inc.

Financials

Balance Sheet Decomposition
Novavax Inc

Current Assets 1.1B
Cash & Short-Term Investments 568.5m
Receivables 297.2m
Other Current Assets 278.1m
Non-Current Assets 653.6m
PP&E 491m
Intangibles 127.5m
Other Non-Current Assets 35.2m
Current Liabilities 1.6B
Accounts Payable 132.6m
Accrued Liabilities 394.7m
Other Current Liabilities 1.1B
Non-Current Liabilities 879.3m
Long-Term Debt 223.9m
Other Non-Current Liabilities 655.3m
Efficiency

Earnings Waterfall
Novavax Inc

Revenue
983.7m USD
Cost of Revenue
-343.3m USD
Gross Profit
640.4m USD
Operating Expenses
-1.2B USD
Operating Income
-552.2m USD
Other Expenses
7.1m USD
Net Income
-545.1m USD

Free Cash Flow Analysis
Novavax Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

NVAX Profitability Score
Profitability Due Diligence

Novavax Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
37/100
Profitability
Score

Novavax Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

NVAX Solvency Score
Solvency Due Diligence

Novavax Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
35/100
Solvency
Score

Novavax Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NVAX Price Targets Summary
Novavax Inc

Wall Street analysts forecast NVAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NVAX is 15.71 USD with a low forecast of 4.04 USD and a high forecast of 39.9 USD.

Lowest
Price Target
4.04 USD
3% Downside
Average
Price Target
15.71 USD
279% Upside
Highest
Price Target
39.9 USD
861% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

NVAX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NVAX Price
Novavax Inc

1M 1M
-14%
6M 6M
-34%
1Y 1Y
-46%
3Y 3Y
-98%
5Y 5Y
-59%
10Y 10Y
-95%
Annual Price Range
4.15
52w Low
3.76
52w High
9.74
Price Metrics
Average Annual Return 573.52%
Standard Deviation of Annual Returns 1 229.51%
Max Drawdown -99%
Shares Statistics
Market Capitalization 578.9m USD
Shares Outstanding 139 952 992
Percentage of Shares Shorted 36.57%

NVAX Return Decomposition
Main factors of price return

What is price return decomposition?

NVAX News

Other Videos

Last Important Events
Novavax Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Novavax Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Novavax Inc Logo
Novavax Inc

Country

United States of America

Industry

Biotechnology

Market Cap

578.9m USD

Dividend Yield

0%

Description

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 1,541 full-time employees. The firm promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Contact

MARYLAND
Gaithersburg
21 Firstfield Road
+12402682000.0
https://www.novavax.com/

IPO

1973-05-16

Employees

1 541

Officers

President & COO
Mr. John Joseph Trizzino B.S., M.B.A.
Executive VP, CFO & Treasurer
Mr. James Patrick Kelly C.F.A.
Advisor
Mr. Stanley Charles Erck
CEO & Director
Mr. John Charles Jacobs M.B.A.
Executive VP & COO
Mr. Richard P. Crowley
Senior VP & Chief Compliance Officer
Mr. Troy Morgan Esq., J.D.
Show More
Executive VP, Chief Legal Officer & Corporate Secretary
Mr. Mark Casey
Associate Director of Investor & Public Relations
Ms. Erika S. Trahan
Executive VP & Chief Human Resources Officer
Mr. Ian J. Watkins
Executive VP and Chief Corporate Affairs & Advocacy Officer
Ms. Silvia Taylor M.B.A.
Show Less

See Also

Discover More
What is the Intrinsic Value of one NVAX stock?

The intrinsic value of one NVAX stock under the Base Case scenario is 8.32 USD.

Is NVAX stock undervalued or overvalued?

Compared to the current market price of 4.15 USD, Novavax Inc is Undervalued by 50%.